However, Eli Lilly is gaining momentum, and expects significant catalysts that could send its stock price soaring in 2025.

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

Eli Lilly is expanding its menu of direct-to-consumer healthcare offerings. | Eli Lilly is expanding its menu of ...

In the fourth quarter of 2024, Eli Lilly and Company (NYSE:LLY)’s revenue surged 45% to $13.53 billion, fueled by high demand for Mounjaro and Zepbound.

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Streamlined access to authentic, FDA-approved, rigorously-tested Zepbound comes from Sesame’s direct integration with Gifthealth. Zepbound is the first and only FDA-approved dual glucagon-like peptide ...

INDIANAPOLIS: Drugmaker Eli Lilly and Company’s SVP and chief communications officer, Kathryn Beiser, has resigned. Beiser ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility.